195 related articles for article (PubMed ID: 29581775)
1. Increased Paxillin expression in prostate cancer is associated with advanced pathological features, lymph node metastases and biochemical recurrence.
Zheng QS; Chen SH; Wu YP; Chen HJ; Chen H; Wei Y; Li XD; Huang JB; Xue XY; Xu N
J Cancer; 2018; 9(6):959-967. PubMed ID: 29581775
[No Abstract] [Full Text] [Related]
2. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence.
Huang JB; Wu YP; Lin YZ; Cai H; Chen SH; Sun XL; Li XD; Wei Y; Zheng QS; Xu N; Xue XY
J Cell Mol Med; 2020 Apr; 24(8):4698-4706. PubMed ID: 32168432
[TBL] [Abstract][Full Text] [Related]
4. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
[TBL] [Abstract][Full Text] [Related]
6. Reduced Connexin 43 expression is associated with tumor malignant behaviors and biochemical recurrence-free survival of prostate cancer.
Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
Oncotarget; 2016 Oct; 7(41):67476-67484. PubMed ID: 27623212
[TBL] [Abstract][Full Text] [Related]
7. Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence.
Kim DK; Koo KC; Abdel Raheem A; Kim KH; Chung BH; Choi YD; Rha KH
PLoS One; 2016; 11(3):e0152391. PubMed ID: 27031340
[TBL] [Abstract][Full Text] [Related]
8. Overexpression levels of cripto-1 predict poor prognosis in patients with prostate cancer following radical prostatectomy.
Liu Y; Wang J; Yang T; Liu R; Xu Y
Oncol Lett; 2019 Sep; 18(3):2584-2591. PubMed ID: 31452743
[TBL] [Abstract][Full Text] [Related]
9. Association of doublecortin-like kinase 1 with tumor aggressiveness and poor biochemical recurrence-free survival in prostate cancer.
Jiang D; Xiao C; Xian T; Wang L; Mao Y; Zhang J; Pang J
Onco Targets Ther; 2018; 11():1077-1086. PubMed ID: 29535532
[TBL] [Abstract][Full Text] [Related]
10. Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosis.
Ellis CL; Partin AW; Han M; Epstein JI
J Urol; 2013 Dec; 190(6):2068-73. PubMed ID: 23727307
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
Guo J; Wang M; Wang Z; Liu X
PLoS One; 2016; 11(8):e0158667. PubMed ID: 27537362
[TBL] [Abstract][Full Text] [Related]
12. Familial prostate cancer: a different disease?
Kupelian PA; Klein EA; Witte JS; Kupelian VA; Suh JH
J Urol; 1997 Dec; 158(6):2197-201. PubMed ID: 9366343
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in lymph node-positive prostate cancer.
Hofer MD; Kuefer R; Huang W; Li H; Bismar TA; Perner S; Hautmann RE; Sanda MG; Gschwend JE; Rubin MA
Urology; 2006 May; 67(5):1016-21. PubMed ID: 16698361
[TBL] [Abstract][Full Text] [Related]
15. L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer.
Koutalellis G; Stravodimos K; Avgeris M; Mavridis K; Scorilas A; Lazaris A; Constantinides C
BJU Int; 2012 Sep; 110(6 Pt B):E267-73. PubMed ID: 22571720
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. Nondissection of pelvic lymph nodes does not influence the results of perineal radical prostatectomy in selected patients.
Salomon L; Hoznek A; Lefrère-Belda MA; Bellot J; Chopin DK; Abbou CC
Eur Urol; 2000 Mar; 37(3):297-300. PubMed ID: 10720855
[TBL] [Abstract][Full Text] [Related]
18. Does bilateral seminal vesicle invasion at radical prostatectomy predict worse prognosis than unilateral invasion among patients with pT3b prostate cancers?
Lee HJ; Han JH; Lee DH; Nam JK; Kim TN; Chung MK; Park SW
Int J Urol; 2016 Sep; 23(9):758-63. PubMed ID: 27305865
[TBL] [Abstract][Full Text] [Related]
19. [miR-129 in the diagnosis, treatment and prediction of clinical prognosis of prostate cancer].
Zhao XD; Tang ZL; Wang ZH; Dong J; Xu S
Zhonghua Nan Ke Xue; 2022 Nov; 28(11):996-1005. PubMed ID: 37846115
[TBL] [Abstract][Full Text] [Related]
20. External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer.
Roumiguié M; Beauval JB; Filleron T; Benoit T; Rischmann P; de la Taille A; Salomon L; Soulié M; Malavaud B; Ploussard G
BJU Int; 2014 Dec; 114(6b):E113-E119. PubMed ID: 24684584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
